Compare Incyte Corporation (INCY) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Royal Bank of Canada — how do they compare? Incyte Corporation trades at $113.34 (market cap $22.85B), while Royal Bank of Canada trades at $191.83 (market cap $262.99B). The key difference: Royal Bank of Canada is far larger — about 11.5× Incyte Corporation's market cap, and Royal Bank of Canada pays a 2.66% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Royal Bank of Canada for 47 Days on average.
| INCY | RY | |
|---|---|---|
Market Cap | $22.85B | $262.99B |
Volume | 1,927,029 | 1,016,377 |
Sector | Health | Financials |
52-Week High | $129.93 | $217.87 |
52-Week Low | $83.80 | $143.64 |
Typical Hold Time | 33 Days | 47 Days |
Enterprise Value | $18.35B | $730.11B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Royal Bank of Canada (RY) trades at $191.33, up 0.06% on the day, with a bearish technical signal and key support at $189. The company reported strong earnings, beating estimates for three consecutive quarters, with Q3 2026 EPS of $3.07 versus $2.89 expected. Revenue grew to $66.53B in 2025, and net income margin improved to 32.01%. Analyst sentiment is mixed, with 43% buy ratings but technical indicators showing selling pressure.
RY's outlook is supported by solid profitability and dividend payments, but faces risks from stretched valuations and negative cash flow trends. The stock's current bearish technical stance and high debt levels warrant caution, though institutional interest remains. Upside depends on sustained earnings growth and effective cost management amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
